M&A / Deals Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout Pharmaceutical TechnologyIf approved, Perfuse's PER-001 could continue Bayer's ophthalmology legacy defined by blockbuster retinal disease therapy, Eylea.OphthalmologyRead full story pharminent May 6, 2026 (Last updated: May 6, 2026) Pharmaceutical Technology If approved, Perfuse’s PER-001 could continue Bayer’s ophthalmology legacy defined by blockbuster retinal disease therapy, Eylea. Ophthalmology Read full story Post navigation Previous: Lilly inflates US facility investment spending by $4.5bnNext: Novo hikes guidance on Wegovy pill’s fast sales start Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026